XML 47 R36.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue - Schedule of Revenue by Sales Category (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Segment Reporting Information [Line Items] |  |  |  |
Net sales | $ 11,142 | $ 10,377 | $ 21,500 | $ 20,341
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 4,276 | 3,934 | 8,444 | 7,780
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 6,866 | 6,443 | 13,056 | 12,561
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 11,137 | 10,373 | 21,492 | 20,334
Operating Segments | Established Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,383 | 1,294 | 2,643 | 2,520
Operating Segments | Established Pharmaceuticals | Key Emerging Markets |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,059 | 988 | 2,024 | 1,916
Operating Segments | Established Pharmaceuticals | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 324 | 306 | 619 | 604
Operating Segments | Nutritional Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,212 | 2,150 | 4,358 | 4,218
Operating Segments | Nutritional Products | Pediatric Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,054 | 1,059 | 2,095 | 2,068
Operating Segments | Nutritional Products | Adult Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,158 | 1,091 | 2,263 | 2,150
Operating Segments | Diagnostic Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,173 | 2,195 | 4,227 | 4,409
Operating Segments | Diagnostic Products | Core Laboratory |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,358 | 1,329 | 2,535 | 2,534
Operating Segments | Diagnostic Products | Molecular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 123 | 127 | 245 | 256
Operating Segments | Diagnostic Products | Point of Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 148 | 156 | 290 | 295
Operating Segments | Diagnostic Products | Rapid Diagnostics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 544 | 583 | 1,157 | 1,324
Operating Segments | Medical Devices |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 5,369 | 4,734 | 10,264 | 9,187
Operating Segments | Medical Devices | Rhythm Management |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 673 | 607 | 1,258 | 1,169
Operating Segments | Medical Devices | Electrophysiology |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 700 | 627 | 1,329 | 1,214
Operating Segments | Medical Devices | Heart Failure |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 368 | 321 | 707 | 626
Operating Segments | Medical Devices | Vascular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 757 | 724 | 1,467 | 1,413
Operating Segments | Medical Devices | Structural Heart |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 636 | 564 | 1,213 | 1,079
Operating Segments | Medical Devices | Neuromodulation |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 254 | 243 | 482 | 469
Operating Segments | Medical Devices | Diabetes Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,981 | 1,648 | 3,808 | 3,217
Operating Segments | United States | Established Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 0 | 0 | 0 | 0
Operating Segments | United States | Established Pharmaceuticals | Key Emerging Markets |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 0 | 0 | 0 | 0
Operating Segments | United States | Established Pharmaceuticals | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 0 | 0 | 0 | 0
Operating Segments | United States | Nutritional Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 957 | 933 | 1,912 | 1,811
Operating Segments | United States | Nutritional Products | Pediatric Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 587 | 564 | 1,175 | 1,078
Operating Segments | United States | Nutritional Products | Adult Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 370 | 369 | 737 | 733
Operating Segments | United States | Diagnostic Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 811 | 812 | 1,682 | 1,743
Operating Segments | United States | Diagnostic Products | Core Laboratory |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 351 | 327 | 683 | 637
Operating Segments | United States | Diagnostic Products | Molecular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 35 | 33 | 75 | 75
Operating Segments | United States | Diagnostic Products | Point of Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 104 | 107 | 204 | 205
Operating Segments | United States | Diagnostic Products | Rapid Diagnostics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 321 | 345 | 720 | 826
Operating Segments | United States | Medical Devices |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,503 | 2,185 | 4,842 | 4,219
Operating Segments | United States | Medical Devices | Rhythm Management |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 340 | 292 | 644 | 563
Operating Segments | United States | Medical Devices | Electrophysiology |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 322 | 287 | 621 | 556
Operating Segments | United States | Medical Devices | Heart Failure |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 282 | 244 | 544 | 481
Operating Segments | United States | Medical Devices | Vascular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 283 | 275 | 551 | 529
Operating Segments | United States | Medical Devices | Structural Heart |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 289 | 258 | 571 | 491
Operating Segments | United States | Medical Devices | Neuromodulation |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 193 | 192 | 369 | 373
Operating Segments | United States | Medical Devices | Diabetes Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 794 | 637 | 1,542 | 1,226
Operating Segments | International | Established Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,383 | 1,294 | 2,643 | 2,520
Operating Segments | International | Established Pharmaceuticals | Key Emerging Markets |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,059 | 988 | 2,024 | 1,916
Operating Segments | International | Established Pharmaceuticals | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 324 | 306 | 619 | 604
Operating Segments | International | Nutritional Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,255 | 1,217 | 2,446 | 2,407
Operating Segments | International | Nutritional Products | Pediatric Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 467 | 495 | 920 | 990
Operating Segments | International | Nutritional Products | Adult Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 788 | 722 | 1,526 | 1,417
Operating Segments | International | Diagnostic Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,362 | 1,383 | 2,545 | 2,666
Operating Segments | International | Diagnostic Products | Core Laboratory |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,007 | 1,002 | 1,852 | 1,897
Operating Segments | International | Diagnostic Products | Molecular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 88 | 94 | 170 | 181
Operating Segments | International | Diagnostic Products | Point of Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 44 | 49 | 86 | 90
Operating Segments | International | Diagnostic Products | Rapid Diagnostics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 223 | 238 | 437 | 498
Operating Segments | International | Medical Devices |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,866 | 2,549 | 5,422 | 4,968
Operating Segments | International | Medical Devices | Rhythm Management |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 333 | 315 | 614 | 606
Operating Segments | International | Medical Devices | Electrophysiology |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 378 | 340 | 708 | 658
Operating Segments | International | Medical Devices | Heart Failure |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 86 | 77 | 163 | 145
Operating Segments | International | Medical Devices | Vascular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 474 | 449 | 916 | 884
Operating Segments | International | Medical Devices | Structural Heart |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 347 | 306 | 642 | 588
Operating Segments | International | Medical Devices | Neuromodulation |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 61 | 51 | 113 | 96
Operating Segments | International | Medical Devices | Diabetes Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,187 | 1,011 | 2,266 | 1,991
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 5 | 4 | 8 | 7
Other | United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 5 | 4 | 8 | 7
Other | International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_MolecularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_PointOfCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_RhythmManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_HeartFailureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_VascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_StructuralHeartMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_NeuromodulationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |